SANARA MEDTECH INC

Company Overview

Sanara MedTech operates two reportable segments: Sanara Surgical, which commercializes soft-tissue repair and bone-fusion products (lead product CellerateRX Surgical plus BIASURGE, FORTIFY, ALLOCYTE Plus, etc.) sold primarily to hospitals, ASCs and post-acute providers through distributors and field reps; and Tissue Health Plus (THP), a developing value‑based wound‑care platform targeting Medicare Advantage and other at‑risk payors with a pilot launched in Q2 2025. The company reported rapid top‑line growth (net revenue +33% to $86.7M in 2024 and continued mid‑20s% YoY growth into 2025) driven by surgical product penetration and higher‑margin mix, while THP remains loss‑making as management invests in platform buildout. Sanara outsources manufacturing, holds a growing IP portfolio and pursues M&A/partnerships, but faces regulatory (FDA/HCT/P, QSR), reimbursement and payer‑adoption risks and relies on a high‑cost secured term loan with escalating revenue covenants.

Executive Compensation Practices

Compensation at Sanara is likely driven by commercial and operational metrics: revenue growth and geographic penetration of surgical products, gross margin/adjusted EBITDA improvement in Sanara Surgical, successful payer contracting and THP pilot commercialization milestones, and successful M&A/integration or IP licensing events. Typical healthcare/medical‑equipment structures expected here include a base salary plus short‑term cash incentives tied to quarterly/annual revenue, margin or EBITDA targets, and long‑term equity (stock options/RSUs) with performance or time‑based vesting keyed to commercialization, regulatory/clinical milestones, and acquisition earnouts. Given the company’s high leverage, lender covenants and near‑term funding needs, compensation plans may include cash‑preservation or covenant‑focused targets and retention awards to keep sales and THP teams during the pilot scale‑up. That mix can create tension between hitting near‑term revenue/covenant targets and longer‑term THP value creation, so look for clawbacks, performance hurdles, or accelerated vesting tied to specific payer contracts or revenue thresholds.

Insider Trading Considerations

Insider trading activity at Sanara is likely to cluster around clearly material events: quarterly results (revenue, covenant status), product launches or clinical results for CellerateRX/BIASURGE, payer contract wins or THP pilot progress, acquisition/earnout milestones, and financings or loan amendments (notably the 13.25% CRG facility and incremental borrowings). Because Sanara is still loss‑making at the THP level, highly leveraged, and has a relatively small public float, insider purchases or sales can be particularly informative (buys may signal confidence in commercialization/covenant compliance; large sales may reflect diversification or financing pressure). Monitor Form 4 filings, 10b5‑1 plan disclosures, option exercises followed by immediate sales, and timing relative to blackout windows — and remember that material non‑public regulatory, reimbursement, or clinical data (HCT/P outcomes, payer agreements) will create legal restrictions and market‑moving potential for insider trades.